AstraZeneca's Lokelma (sodium zirconium cyclosilicate) Receives MHLW's Approval for the Treatment of Hyperkalemia in Japan
Shots:
- The MHLW’s approval is based on stand-alone studies in Japan and global clinical programs and is supported by DIALIZE study that demonstrated the efficacy on Lokelma in treating hyperkalemia patients with ESRD on hemodialysis
- The global clinical program result: @12mos. the median time to achieve normal potassium levels in the blood (22hrs.) with 98% achieving normal levels within 48hrs. The therapy demonstrated a reduction in blood potassium level in 1hr. with 1 dose and a sustained treatment effect for up to 1yr.
- Lokelma is an insoluble- non-absorbed sodium zirconium silicate- formulated as a powder for oral suspension and acts as a highly selective potassium-removing medicine and is an approved therapy for the treatment of hyperkalemia in the US- EU- Canada- Hong Kong- China- Russia and Japan
Click here to read full press release/ article
Ref: AstraZeneca | Image: AstraZeneca
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com